tiprankstipranks
Trending News
More News >
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
US Market
Advertisement

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

Compare
10,172 Followers
See the Price Targets and Ratings of:

CRSP Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
11 Buy
7 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$70.20
▲(27.92% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $70.20 with a high forecast of $105.00 and a low forecast of $40.00. The average price target represents a 27.92% change from the last price of $54.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,59.8523076923077,63.61461538461539,67.37692307692308,71.13923076923078,74.90153846153846,78.66384615384615,82.42615384615385,86.18846153846154,89.95076923076923,93.71307692307693,97.47538461538461,101.2376923076923,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,57.175384615384615,58.260769230769235,59.34615384615385,60.431538461538466,61.51692307692308,62.6023076923077,63.68769230769231,64.77307692307693,65.85846153846154,66.94384615384615,68.02923076923078,69.11461538461539,{"y":70.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,54.8523076923077,53.61461538461539,52.37692307692308,51.13923076923077,49.901538461538465,48.66384615384616,47.42615384615385,46.18846153846154,44.95076923076923,43.713076923076926,42.47538461538461,41.23769230769231,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$105.00Average Price Target$70.20Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CRSP
Evercore ISI
Evercore ISI
$99
Buy
80.39%
Upside
Initiated
08/25/25
Crispr Therapeutics AG (CRSP) Has a New Rating from Evercore ISI
Bernstein
Hold
Reiterated
08/22/25
Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein
TR | OpenAI - 4o Analyst forecast on CRSP
TR | OpenAI - 4o
TR | OpenAI - 4o
$60$55
Hold
0.22%
Upside
Reiterated
08/11/25
AI Generated ArticleAI Generated Article
Truist Financial Analyst forecast on CRSP
Truist Financial
Truist Financial
$100
Buy
82.22%
Upside
Reiterated
08/08/25
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on CRSP
H.C. Wainwright
H.C. Wainwright
$65$80
Buy
45.77%
Upside
Reiterated
08/07/25
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating
Chardan Capital Analyst forecast on CRSP
Chardan Capital
Chardan Capital
$82
Buy
49.42%
Upside
Reiterated
08/05/25
Chardan Capital Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Goldman Sachs Analyst forecast on CRSP
Goldman Sachs
Goldman Sachs
$48
Hold
-12.54%
Downside
Reiterated
08/05/25
Goldman Sachs Remains a Hold on Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CRSP
Barclays
Barclays
$42$56
Hold
2.04%
Upside
Reiterated
08/05/25
Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)
William Blair Analyst forecast on CRSP
William Blair
William Blair
Buy
Reiterated
08/05/25
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating
Needham Analyst forecast on CRSP
Needham
Needham
$81
Buy
47.59%
Upside
Reiterated
08/05/25
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth
TD Cowen
$35$40
Hold
-27.11%
Downside
Reiterated
08/05/25
Cautious Hold Rating for Casgevy Amid Growth and Upcoming Data ReleasesWe have added CTX310 to our model and increased our PT to $40.
Leerink Partners Analyst forecast on CRSP
Leerink Partners
Leerink Partners
$56
Buy
2.04%
Upside
Reiterated
08/05/25
Crispr Therapeutics AG (CRSP) Receives a Buy from Leerink Partners
RBC Capital Analyst forecast on CRSP
RBC Capital
RBC Capital
$38$42
Hold
-23.47%
Downside
Reiterated
08/05/25
RBC Capital Remains a Hold on Crispr Therapeutics AG (CRSP)
Bank of America Securities Analyst forecast on CRSP
Bank of America Securities
Bank of America Securities
$79$78
Buy
42.13%
Upside
Reiterated
07/22/25
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities
Citizens JMP Analyst forecast on CRSP
Citizens JMP
Citizens JMP
$86
Buy
56.71%
Upside
Reiterated
06/27/25
Citizens JMP Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CRSP
Evercore ISI
Evercore ISI
$99
Buy
80.39%
Upside
Initiated
08/25/25
Crispr Therapeutics AG (CRSP) Has a New Rating from Evercore ISI
Bernstein
Hold
Reiterated
08/22/25
Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein
TR | OpenAI - 4o Analyst forecast on CRSP
TR | OpenAI - 4o
TR | OpenAI - 4o
$60$55
Hold
0.22%
Upside
Reiterated
08/11/25
AI Generated ArticleAI Generated Article
Truist Financial Analyst forecast on CRSP
Truist Financial
Truist Financial
$100
Buy
82.22%
Upside
Reiterated
08/08/25
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on CRSP
H.C. Wainwright
H.C. Wainwright
$65$80
Buy
45.77%
Upside
Reiterated
08/07/25
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating
Chardan Capital Analyst forecast on CRSP
Chardan Capital
Chardan Capital
$82
Buy
49.42%
Upside
Reiterated
08/05/25
Chardan Capital Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Goldman Sachs Analyst forecast on CRSP
Goldman Sachs
Goldman Sachs
$48
Hold
-12.54%
Downside
Reiterated
08/05/25
Goldman Sachs Remains a Hold on Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CRSP
Barclays
Barclays
$42$56
Hold
2.04%
Upside
Reiterated
08/05/25
Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)
William Blair Analyst forecast on CRSP
William Blair
William Blair
Buy
Reiterated
08/05/25
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating
Needham Analyst forecast on CRSP
Needham
Needham
$81
Buy
47.59%
Upside
Reiterated
08/05/25
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth
TD Cowen
$35$40
Hold
-27.11%
Downside
Reiterated
08/05/25
Cautious Hold Rating for Casgevy Amid Growth and Upcoming Data ReleasesWe have added CTX310 to our model and increased our PT to $40.
Leerink Partners Analyst forecast on CRSP
Leerink Partners
Leerink Partners
$56
Buy
2.04%
Upside
Reiterated
08/05/25
Crispr Therapeutics AG (CRSP) Receives a Buy from Leerink Partners
RBC Capital Analyst forecast on CRSP
RBC Capital
RBC Capital
$38$42
Hold
-23.47%
Downside
Reiterated
08/05/25
RBC Capital Remains a Hold on Crispr Therapeutics AG (CRSP)
Bank of America Securities Analyst forecast on CRSP
Bank of America Securities
Bank of America Securities
$79$78
Buy
42.13%
Upside
Reiterated
07/22/25
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities
Citizens JMP Analyst forecast on CRSP
Citizens JMP
Citizens JMP
$86
Buy
56.71%
Upside
Reiterated
06/27/25
Citizens JMP Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

1 Month
xxx
Success Rate
13/21 ratings generated profit
62%
Average Return
+10.18%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +10.18% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
57%
Average Return
+8.11%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +8.11% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
11/21 ratings generated profit
52%
Average Return
+8.81%
reiterated a buy rating 23 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +8.81% per trade.
2 Years
xxx
Success Rate
11/21 ratings generated profit
52%
Average Return
+2.47%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.38% of your transactions generating a profit, with an average return of +2.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
18
24
30
25
9
Buy
2
5
10
12
12
Hold
16
17
19
21
18
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
46
59
58
39
In the current month, CRSP has received 21 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the past 3 months is 70.20.
Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.24 with a range of -$1.67 to -$0.92. The previous quarter’s EPS was -$2.40. CRSP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.10% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.
Next quarter’s earnings estimate for CRSP is -$1.24 with a range of -$1.67 to -$0.92. The previous quarter’s EPS was -$2.40. CRSP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.10% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $10.98M with a range of $0.00 to $44.36M. The previous quarter’s sales results were $892.00K. CRSP beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.87% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.
Next quarter’s sales forecast for CRSP is $10.98M with a range of $0.00 to $44.36M. The previous quarter’s sales results were $892.00K. CRSP beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.87% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is 70.20.
    What is CRSP’s upside potential, based on the analysts’ average price target?
    Crispr Therapeutics AG has 27.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRSP a Buy, Sell or Hold?
          Crispr Therapeutics AG has a consensus rating of Moderate Buy which is based on 11 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Crispr Therapeutics AG’s price target?
            The average price target for Crispr Therapeutics AG is 70.20. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $105.00 ,the lowest forecast is $40.00. The average price target represents 27.92% Increase from the current price of $54.88.
              What do analysts say about Crispr Therapeutics AG?
              Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of CRSP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis